FORM 6-K

SECURITIES AND EXCHANGE COMMISSION FINER

Washington D.C. 20549

Report of Foreign Issuer



Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

7.8. For 29 April, 2002

> GlaxoSmithKline plc (Name of registrant)

PROCESSED

MAY 2 0 2002

THOMSON **FINANCIAL**

GLAXOSMITHKLINE, 980 GREAT WEST ROAD, BRENTFORD, MIDDLESEX TW8 9GS (Address of principal executive offices)

Indicated by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ____ Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ____ No ___



GlaxoSmithKline plc 980 Great West Road Brentford Middlesex TW8 9GS

Tel. +44 (0)20 8047 5000 www.gsk.com

Directors' Interests

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

26 April 2002

The Administrators of the SmithKline Beecham Employee Benefit Trust ("the Trust") notified the Company on the 29 April 2002 that 1,449,617 Ordinary shares had been transferred from the Trust to participants of the SmithKline Beecham 1991 Share Option Plan.

The Trust is a discretionary fund of which all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two of the Company's directors, Dr J P Garnier and John Coombe are therefore interested in the shares held in the fund from time to time in the same way as other employees or former employees of GlaxoSmithKline plc and its subsidiaries.

S M Bicknell Company Secretary

29 April 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date:

29 April, 2002

By:

ORRAINE DAY

Authorised Signatory for and on behalf of GlaxoSmithKline plc